Skip to main content
Blood Advances logoLink to Blood Advances
. 2021 Jul 9;5(13):2752. doi: 10.1182/bloodadvances.2021005193

Zhou Z, Nath R, Cerny J, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.

PMCID: PMC8270564  PMID: 34242389

In “Acknowledgments” on page 3188, National Heart, Lung, and Blood Institute (NHLBI) grant OT3HL147741 should not have been cited. The error has been corrected in the published article.


Articles from Blood Advances are provided here courtesy of The American Society of Hematology

RESOURCES